• 1
    Weinbaum C, Lyerla R, Margolis HS; for Centers for Disease Control and Prevention. Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003; 52: 1-36.
  • 2
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714.
  • 3
    Spaulding AC, Weinbaum CM, Lau DT, Sterling R, Seeff LB, Margolis HS, et al. A framework for management of hepatitis C in prisons. Ann Intern Med 2006; 144: 762-769.
  • 4
    Harzke AJ, Baillargeon J, Paar DP, Pulvino J, Murray OJ. Chronic liver disease mortality among male prison inmates in Texas, 1989–2003. Am J Gastroenterol 2009; 104: 1412-1419.
  • 5
    Aronsohn A, Jensen D. The long-term horizon: patients who will remain untreated in the era of triple therapy. Clinical Liver Disease 2012; 1: 20-23.
  • 6
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
  • 7
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FLJr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
  • 8
    Baillargeon J, Binswanger IA, Penn JV, Williams BA, Murray OJ. Psychiatric disorders and repeat incarcerations: the revolving prison door. Am J Psychiatry 2009; 166: 103-109.
  • 9
    Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med 2003; 138: 187-190.
  • 10
    Sterling RK, Hofmann CM, Luketic VA, Sanyal AJ, Contos MJ, Mills AS, et al. Treatment of chronic hepatitis C virus in the Virginia department of corrections: can compliance overcome racial differences to response? Am J Gastroenterol 2004; 99: 866-872.
    Direct Link:
  • 11
    Chew KW, Allen SA, Taylor LE, Rich JD, Feller E. Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C. J Clin Gastroenterol 2009; 43: 686-691.
  • 12
    Strock P, Mossong J, Hawotte K, Arendt V. Access to treatment of hepatitis C in prison inmates. Dig Dis Sci 2009; 54: 1325-1330.
  • 13
    Maru DS, Bruce RD, Basu S, Altice FL. Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clin Infect Dis 2008; 47: 952-961.
  • 14
    Rice JP, Burnett D, Tsotsis H, Lindstrom MJ, Cornett DD, Voermans P, et al. Comparison of hepatitis C virus treatment between incarcerated and community patients. Hepatology; doi:10.1002/hep.25770.